Altimmune, Inc. is a clinical stage biopharmaceutical company based in Maryland, USA. It specializes in developing treatments for obesity and liver related diseases such as non-alcoholic steatohepatitis and hepatitis B virus. The company's most promising product candidates include pemvidutide, which is undergoing clinical trials for obesity and non-alcoholic steatohepatitis, and HepTcell, which is currently in Phase 2 for chronically infected hepatitis B patients.